Market Cap
$2.1B
TRVI
Trevi Therapeutics, Inc.
$14.40 ▲ +1.52%
Prev close $14.18Market cap$2.1B
ConsensusStrong Buy
12-mo target$28.18 (+95.8%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10)23 New Institutional Positions12 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on TRVI right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (94%)
Inst. Holders
50 funds
Inst. Value
$1.5B
Inst. Activity
23 buys / 12 sells
Insider Activity
$0.00 buy / $594.2K sell
Insider Net $
-$594.2K
SEC Reports
5
Press Releases
5
Price chart 30d -15.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Short Volume: TRVI — 66.6% short (0.6M / 0.8M)
Short: 562,240 | Exempt: 0 | TRF Vol: 844,799 | Short Ratio: 66.6% | Off-exchange volume (dark pool
Sep 15, 2026 Insider
Heffernan Michael Thomas acquired via exercise 18,421 shares
Director @ $3.04 ($56.0K)
Sep 15, 2026 Insider
Heffernan Michael Thomas sold 18,321 shares
Director @ $15.09 ($276.5K)
Sep 15, 2026 Insider
Heffernan Michael Thomas sold 100 shares
Director @ $15.88 ($1.6K)
Jun 30, 2026 Inst.
FMR LLC — ADD
12,562,839 shares ($234.3M)
Jun 30, 2026 Inst.
Jun 11, 2026 SEC Woodline Partners LP — DOUBLED
4,081,333 shares ($76.1M)
Four institutional buyers accumulated $90.6M in TRVI during Q4 2025, led by Fidelity ($51.2M add) and AllianceBernstein
INST-CLUSTER — Impact 5/10
A strong institutional cluster for Trevi Therapeutics (TRVI) in Q3 2025 shows 8 buyers adding $111.4M in aggregate holdi
INST-CLUSTER — Impact 4/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
94% rate it Buy or better · 18 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 14, 2026 | Jones Trading | MAINTAIN | Buy | 51% |
| Aug 7, 2026 | Oppenheimer | MAINTAIN | Outperform | 52% |
| Aug 7, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | 49% |
| Jul 21, 2026 | BMO Capital | INITIATE | Outperform | 53% |
| Jul 20, 2026 | B. Riley Securities | MAINTAIN | Buy | 54% |
| Jul 20, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| May 20, 2026 | Needham | REITERATE | Buy | 50% |
| May 6, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 6, 2026 | Needham | MAINTAIN | Buy | 50% |
| Apr 17, 2026 | D. Boral Capital | MAINTAIN | Buy | 33% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Aug 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Jul 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| Jun 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% |
Price targets
Where 11 covering analysts think TRVI trades over the next 12 months.
$28.18 +95.8% upside Strong Buy
Current$14.40 Low$23.00 Median$25.00 High$40.00 11 analysts
$23.00$40.00
Analyst rating Strong Buy· 1.2/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 0 bullish, 2 bearish, 2 mixed, 1 neutral · avg impact 5.2/10.Plus 5 press releases.
MIXEDINST-CLUSTER5/10
Four institutional buyers accumulated $90.6M in TRVI during Q4 2025, led by Fidelity ($51.2M add) an
Jun 11, 2026
MIXEDINST-CLUSTER4/10
A strong institutional cluster for Trevi Therapeutics (TRVI) in Q3 2025 shows 8 buyers adding $111.4
Jun 11, 2026
NEUTRALDEFA14A3/10
Trevi Therapeutics is holding its 2026 annual meeting where shareholders will vote on several propos
Apr 21, 2026
BEARISH424B57/10
Trevi Therapeutics priced a $150.8 million follow-on offering of 11.6 million shares at $13.00 per s
Apr 17, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: TRVI — 66.6% short (0.6M / 0.8M)
Short: 562,240 | Exempt: 0 | TRF Vol: 844,799 | Short Ratio: 66.6% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
short_volume
Short Volume: TRVI — 71.2% short (0.7M / 1.0M)
Short: 732,986 | Exempt: 0 | TRF Vol: 1,029,985 | Short Ratio: 71.2% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: TRVI — 73.0% short (0.7M / 1.0M)
Short: 706,984 | Exempt: 0 | TRF Vol: 968,133 | Short Ratio: 73.0% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: TRVI — 74.4% short (0.5M / 0.7M)
Short: 536,045 | Exempt: 0 | TRF Vol: 720,276 | Short Ratio: 74.4% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: TRVI — 71.5% short (0.4M / 0.6M)
Short: 416,824 | Exempt: 0 | TRF Vol: 582,991 | Short Ratio: 71.5% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.13 | $-0.18–$-0.11 | -66.3% | +0.0% | 0↑ 1↓ | $0.0B | 10 |
| Next Q | $-0.14 | $-0.20–$-0.07 | -138.3% | +0.0% | 1↑ 2↓ | $0.0B | 10 |
| Current FY | $-0.48 | $-0.58–$-0.34 | -49.7% | +0.0% | 1↑ 7↓ | $0.0B | 10 |
| Next FY | $-0.58 | $-0.76–$-0.40 | -20.5% | +0.0% | 1↑ 5↓ | $0.0B | 10 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.133 | — |
| 7d ago | $-0.133 | — |
| 30d ago | $-0.133 | — |
| 60d ago | $-0.129 | -0.004 |
| 90d ago | $-0.129 | -0.004 |
Institutional ownership
Which big funds own TRVI (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.5B total value (80,241,977 shares) as of 2026-Q2. Top holders: NOMURA, FMR, BlackRock,. Net buying activity: 23 institutions added/increased vs 12 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| FMR LLC | 12,562,839 | $234.3M | 15.8% | ADD +56.3% |
| BlackRock, Inc. | 11,155,026 | $208.0M | 14.1% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 5,684,592 | $106.0M | 7.2% | ADD +52.4% |
| VANGUARD CAPITAL MANAGEMENT LLC | 5,530,675 | $103.1M | 7.0% | — |
| Woodline Partners LP | 4,081,333 | $76.1M | 5.1% | DOUBLED +307.8% |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 3,070,740 | $57.3M | 3.9% | ADD +54.0% |
| STATE STREET CORP | 3,027,315 | $56.5M | 3.8% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 2,928,068 | $54.6M | 3.7% | — |
| MARSHALL WACE, LLP | 2,674,137 | $49.9M | 3.4% | TRIM -32.6% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| FMR LLC | ADD | 8,038,061 | 12,562,839 | +56.3% | $234.3M |
| Woodline Partners LP | DOUBLED | 1,000,782 | 4,081,333 | +307.8% | $76.1M |
| FRONTIER CAPITAL MANAGEMENT CO LLC | ADD | 1,994,292 | 3,070,740 | +54.0% | $57.3M |
| MARSHALL WACE, LLP | TRIM | 3,966,019 | 2,674,137 | -32.6% | $49.9M |
| Rubric Capital Management LP | TRIM | 3,712,373 | 2,504,513 | -32.5% | $46.7M |
| VIKING GLOBAL INVESTORS LP | TRIM | 3,198,644 | 1,544,644 | -51.7% | $28.8M |
| BANK OF AMERICA CORP /DE/ | ADD | 1,216,955 | 1,532,889 | +26.0% | $28.6M |
| Assenagon Asset Management S.A. | NEW | — | 1,525,314 | — | $28.4M |
| BARCLAYS PLC | DOUBLED | 53,585 | 1,142,077 | +2031.3% | $21.3M |
| BALYASNY ASSET MANAGEMENT L.P. | ADD | 473,849 | 845,087 | +78.3% | $15.8M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 15 transactions. Net -$594.2K — $0.00 bought, $594.2K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Heffernan Michael Thomas | Director | EXERCISE | 18,421 | $3.04 | $56.0K |
| Sep 15, 2026 | Heffernan Michael Thomas | Director | SELL | 18,321 | $15.09 | $276.5K |
| Sep 15, 2026 | Heffernan Michael Thomas | Director | SELL | 100 | $15.88 | $1.6K |
| Sep 15, 2026 | Heffernan Michael Thomas | Director | EXERCISE | 21,052 | $3.33 | $70.1K |
| Sep 15, 2026 | Heffernan Michael Thomas | Director | SELL | 20,952 | $15.09 | $316.2K |
| Jun 3, 2026 | Heffernan Michael Thomas | Director | AWARD | 35,000 | — | — |
| Jun 3, 2026 | Colangelo Dominick | Director | AWARD | 35,000 | — | — |
| Jun 3, 2026 | Meeker David P | Director | AWARD | 35,000 | — | — |
| Jun 3, 2026 | VANLENT ANNE | Director | AWARD | 35,000 | — | — |
| Jun 3, 2026 | Mathers Edward T | Director | AWARD | 35,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TRVI.
Shares short
12,070,625
Settlement Sep 15, 2026
Change vs prior
+0.5%
Semi-monthly cycle
Days to cover
8.8
At avg daily volume
Of shares outstanding
≈8.5%
Estimate — not % of float
All TRVI filing & press-release reports (10)
- INST-CLUSTER reportJun 11, 2026
- INST-CLUSTER reportJun 11, 2026
- DEFA14A reportApr 21, 2026
- PRESS-RELEASE reportApr 20, 2026
- 424B5 reportApr 17, 2026
- 8-K reportApr 17, 2026
- PRESS-RELEASE reportApr 17, 2026
- PRESS-RELEASE reportMar 17, 2026
- PRESS-RELEASE reportMar 10, 2026
- PRESS-RELEASE reportMar 9, 2026